Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients with AIDS Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients with AIDS conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients with AIDS Clinical research trials and A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients with AIDS medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients with AIDS. A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients with AIDS Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients with AIDS clinical trial. Subjects often receive the most expert healthcare possible for their A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients with AIDS condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients with AIDS

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients with AIDS



A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients with AIDS

For Condition: Colitis,HIV Infections
Status: Completed
Sponsor(s): Hoffmann-La Roche ,
Synopsis: To attempt to demonstrate the efficacy of ganciclovir (DHPG) treatment of cytomegalovirus (CMV) colitis in AIDS patients by evaluating both clinical and virologic parameters. To determine acceptability and the safety profile of a 2-week course of intravenous (IV) DHPG therapy.
Details:
Eligibility:
Study Type:  Interventional, Treatment, Double-Blind
Minimum Age/Maximum Age: 21 Years/
Genders: Male
Protocol Entry Criteria: Inclusion Criteria Patients must have: - An underlying diagnosis of AIDS by CDC surveillance definition (group IV, category c-1 or subgroup D only). - Colitis manifested clinically by diarrhea. - Colon biopsy demonstrating a typical histologic picture of cytomegalovirus (CMV) disease. - Cultures for CMV from blood and urine should be obtained within 1 week of study entry but need not be positive prior to entry. (A positive culture is needed for final inclusion in AN.) Prior Medication: Allowed: - Topical acyclovir. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - History of chronic or acute liver disease. - History of significant mental illness. - Life expectancy < 1 month. - Presence of any cause of colitis other than cytomegalovirus (CMV). (The following tests must be negative: - Stool culture for enteric bacterial pathogens, stool exam for ova and parasites, stool exam for cryptosporidia, stool exam for AFB.) Colitis that is so severe that it would be against the patient's best interest to be treated with placebo for 2 weeks prior to being eligible to receive ganciclovir (DHPG) on a "compassionate" use basis. Patients with a colitis of this severity should be treated with DHPG on "compassionate" use basis. - Presence of clinically significant extra-colonic active CMV disease of retina or visceral organs (which could progress during the no-treatment period). - Presence of significant renal disease resulting in any decrement of creatinine clearance from normal. Concurrent Medication: Excluded: - Any other investigational drug, whether or not as part of a formal clinical study. Patients with the following are excluded: - History of chronic or acute liver disease. - History of significant mental illness. - Life expectancy < 1 month. - Presence of any cause of colitis other than cytomegalovirus (CMV). (The following tests must be negative: - Stool culture for enteric bacterial pathogens, stool exam for ova and parasites, stool exam for cryptosporidia, stool exam for AFB.) Colitis that is so severe that it would be against the patient's best interest to be treated with placebo for 2 weeks prior to being eligible to receive ganciclovir (DHPG) on a "compassionate" use basis. Patients with a colitis of this severity should be treated with DHPG on "compassionate" use basis. - Presence of clinically significant extra-colonic active CMV disease of retina or visceral organs (which could progress during the no-treatment period). - Presence of significant renal disease resulting in any decrement of creatinine clearance from normal. Prior Medication: Excluded within 2 days of study entry: - Nucleoside analogs. - Excluded within 1 week of study entry: - Antimetabolites or interferon.
Total Enrollment: 

Location and Contact Information:

Roche Global Development - Palo Alto
Palo Alto,  California,  94303
United States
 


Additional Information:
Study ID Numbers:  029C;  ICM 1288
Study Start Date: 
Record last reviewed: September 1989
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002273

Other Colitis Studies:
1. A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients

2. A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients with AIDS

3. A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn’s Disease

Related Studies:

Other Colitis Clinical Trials
Other California Clinical Trials
Other Palo Alto Clinical Trials

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients with AIDS
Modify your Search

  Other Colitis Clinical Trials
  Other California Clinical Trials
  Other Palo Alto Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103